MetaVia Inc. Files 8-K
Ticker: MTVA · Form: 8-K · Filed: Nov 29, 2024 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Metavia INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Nov 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-disclosure, filing
Related Tickers: MTVA
TL;DR
MetaVia Inc. (MTVA) filed an 8-K on 11/29/24, updating its corporate info.
AI Summary
MetaVia Inc. filed an 8-K on November 29, 2024, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc., is incorporated in Delaware and based in Cambridge, MA.
Why It Matters
This filing provides an update on MetaVia Inc.'s corporate status and reporting, which is crucial for investors to stay informed about the company's regulatory compliance and financial disclosures.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- MetaVia Inc. (company) — Registrant
- NeuroBo Pharmaceuticals, Inc. (company) — Former Company Name
- Gemphire Therapeutics Inc. (company) — Former Company Name
- November 29, 2024 (date) — Date of Report
- Cambridge, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for MetaVia Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 29, 2024.
What were MetaVia Inc.'s previous names?
MetaVia Inc. was formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc.
Where are MetaVia Inc.'s principal executive offices located?
MetaVia Inc.'s principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.
What is MetaVia Inc.'s Standard Industrial Classification code?
MetaVia Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 671 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-11-29 09:10:13
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share MTVA The Nasdaq Stock Mar
Filing Documents
- mtva-20241129x8k.htm (8-K) — 46KB
- mtva-20241129xex99d1.htm (EX-99.1) — 51KB
- mtva-20241129x8k001.jpg (GRAPHIC) — 9KB
- mtva-20241129xex99d1g001.jpg (GRAPHIC) — 86KB
- mtva-20241129xex99d1g002.jpg (GRAPHIC) — 194KB
- mtva-20241129xex99d1g003.jpg (GRAPHIC) — 161KB
- mtva-20241129xex99d1g004.jpg (GRAPHIC) — 119KB
- mtva-20241129xex99d1g005.jpg (GRAPHIC) — 58KB
- mtva-20241129xex99d1g006.jpg (GRAPHIC) — 123KB
- mtva-20241129xex99d1g007.jpg (GRAPHIC) — 93KB
- mtva-20241129xex99d1g008.jpg (GRAPHIC) — 169KB
- mtva-20241129xex99d1g009.jpg (GRAPHIC) — 183KB
- mtva-20241129xex99d1g010.jpg (GRAPHIC) — 131KB
- mtva-20241129xex99d1g011.jpg (GRAPHIC) — 165KB
- mtva-20241129xex99d1g012.jpg (GRAPHIC) — 184KB
- mtva-20241129xex99d1g013.jpg (GRAPHIC) — 239KB
- mtva-20241129xex99d1g014.jpg (GRAPHIC) — 189KB
- mtva-20241129xex99d1g015.jpg (GRAPHIC) — 115KB
- mtva-20241129xex99d1g016.jpg (GRAPHIC) — 99KB
- mtva-20241129xex99d1g017.jpg (GRAPHIC) — 172KB
- mtva-20241129xex99d1g018.jpg (GRAPHIC) — 97KB
- mtva-20241129xex99d1g019.jpg (GRAPHIC) — 127KB
- mtva-20241129xex99d1g020.jpg (GRAPHIC) — 140KB
- mtva-20241129xex99d1g021.jpg (GRAPHIC) — 137KB
- mtva-20241129xex99d1g022.jpg (GRAPHIC) — 146KB
- mtva-20241129xex99d1g023.jpg (GRAPHIC) — 90KB
- mtva-20241129xex99d1g024.jpg (GRAPHIC) — 123KB
- mtva-20241129xex99d1g025.jpg (GRAPHIC) — 123KB
- mtva-20241129xex99d1g026.jpg (GRAPHIC) — 99KB
- mtva-20241129xex99d1g027.jpg (GRAPHIC) — 86KB
- mtva-20241129xex99d1g028.jpg (GRAPHIC) — 120KB
- mtva-20241129xex99d1g029.jpg (GRAPHIC) — 104KB
- 0001558370-24-015952.txt ( ) — 5539KB
- mtva-20241129.xsd (EX-101.SCH) — 3KB
- mtva-20241129_lab.xml (EX-101.LAB) — 16KB
- mtva-20241129_pre.xml (EX-101.PRE) — 10KB
- mtva-20241129x8k_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure . On November 29, 2024, MetaVia Inc. (the "Company") posted an updated corporate presentation to its website at https://www.metaviatx.com/events-presentations/presentations , which the Company may use from time to time in communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K (this "Report"). Information contained on or accessible through any website reference in the corporate presentation is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the corporate presentation is as inactive textual references only. Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company's submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Corporate Presentation dated November 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. METAVIA INC. Date: November 29, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer